Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Cardiac Glycosides

Cardiac Glycosides

Cardiac glycosides are a class of naturally occurring compounds derived from plants that have a direct impact on the heart.
These compounds, which include digoxin and ouabain, interact with the sodium-potassium ATPase pump, altering the electrical activity and contractility of cardiac muscle cells.
Cardiac glycosides are commonly used in the treatment of certain heart conditions, such as atrial fibrillation and heart failure, where they can help improve heart function and reduce symptoms.
Researchers studiying the therapeutic potential and mechanisms of cardiac glycosides can utilize PubCompare.ai's AI-driven platform to easily identify optimized research protocols from the literature, preprints, and patents, ensuring their work is accurate and reproducable.
Discover the future of scientific discovery with PubCompare.ai today.

Most cited protocols related to «Cardiac Glycosides»

1
Enzymatic Polysaccharide Hydrolysis Assays
Cited 20 times
The enzymatic hydrolysis of polysaccharides was carried out at pH 5.0 and 50°C in thermostated test tubes (2 mL); in all cases the substrate concentration was 5 mg/mL. The RSs released in hydrolysis were analyzed using the NS [3 , 4 (link)] and DNS [5 ] assays modified to smaller volumes (see below). The carbohydrase activities were expressed in international units where one activity unit corresponds to the amount of the enzyme hydrolyzing 1 μmoL of glycoside bonds of the substrate per minute. All assays were carried out in duplicates.
NS Assay

An aliquot of the substrate stock solution (0.16 mL, 6.25 mg/mL in 0.1 M Na-acetate buffer) was preliminary heated at 50°C for 5 min. Then the enzyme reaction was initiated by adding 0.04 mL of the enzyme solution (also preheated at 50°C for 5 min). The mixture was incubated at 50°C for 10 min (5 min in the case of CMCase and β-glucanase activities); the reaction was stopped by addition of 0.2 mL of the Somogyi copper reagent. The tightly stoppered test tube was incubated in a boiling water bath for 40 min; then it was cooled to room temperature and 0.2 mL of the Nelson arsenomolybdate reagent was added. The solution was carefully mixed and incubated for 10 min at room temperature and then 1.4 mL of water was added (0.4 mL of acetone to dissolve the precipitated CMC or β-glucan and then 1 mL of water were added in the case of CMCase and β-glucanase activity measurements). After centrifugation at 13,000 rpm for 1 min, the absorbance of the supernatant at 610 nm (A610) was measured. The A610 values for the substrate and enzyme blanks were subtracted from the A610 value for the analyzed sample. The substrate and enzyme blanks were prepared in the same way as the analyzed sample except that the necessary amount of the acetate buffer was added to the substrate (enzyme) solution instead of the enzyme (substrate) solution.

DNS Assay

An aliquot of the substrate stock solution (0.3 mL, 10 mg/mL in 0.1 M Na-acetate buffer) was mixed with 0.3 mL of the enzyme solution (both solutions were preheated at 50°C for 5 min). After 10 min of incubation at 50°C, 0.9 mL of the DNS reagent was added to the test tube and the mixture was incubated in a boiling water bath for 5 min. After cooling to room temperature, the absorbance of the supernatant at 540 nm was measured. The A540 values for the substrate and enzyme blanks were subtracted from the A540 value for the analyzed sample. The substrate and enzyme blanks were prepared in the same way as the analyzed sample except that 0.3 mL of the acetate buffer was added to the substrate (enzyme) solution instead of the enzyme (substrate) solution.

Gusakov A.V., Kondratyeva E.G, & Sinitsyn A.P. (2011). Comparison of Two Methods for Assaying Reducing Sugars in the Determination of Carbohydrase Activities. International Journal of Analytical Chemistry, 2011, 283658.
Full text: Click here
Publication 2011
Acetate Acetone Bath beta-Glucans Biological Assay Buffers carbohydrase carboxymethylcellulase Cardiac Glycosides Centrifugation Copper Enzymes Hydrolysis Polysaccharides
2
Improved Molecular Dynamics Force Field for DNA
Cited 15 times
The AMBER simulations were carried out with the ff9931 (link), bsc08 (link), χOL39 ,10 (link) and χOL4 (this work) versions of the Cornell et al. force field.5 Bsc0 introduced significant modification to α/γ backbone torsional parameters essential for stability of B-DNA simulations. The χOL3 parametrization modified the χ glycosidic torsions to stabilize RNA simulations. While χOL3 modification can be combined with either ff99 or bsc0 for RNA, it works best in combination with bsc0. All DNA simulations must include bsc0.
ParmχOL4 is a new version of the χ-profile which aims to improve description of the syn region and syn-anti balance while not deteriorating the B-DNA simulations by the anti to high-anti region. The syn region of χOL4 profile differs from that of the RNA χOL3 force field in that it provides narrower and somewhat deeper syn valley than χOL3, thus suppressing the excessive population of χ syn angles in the region of 90–110°. This is a result of using a deoxyribonucleoside model compound instead of the ribonucleoside one for fitting, i.e., the difference is consistent with the primary QM data. When compared to the ff99 force field, χOL4 shifts the syn minimum to the higher χ values by about 10° and apparent are also differences in the barrier heights (Figure 2). Also, the syn minimum is somewhat deeper, which is an opposite trend compared to the χOL3 modification. While the syn region was fitted to the deoxyribonucleoside QM data, the anti to high-anti region has been modified empirically. The reason is that subtle increase of the slope of the χ correction between the anti and high-anti regions as compared to the ff99 supports helical twist of B-DNA. It subtly increases the helical twist of B-DNA (see below) though it remains to be seen if this change can be significant for B-DNA modeling. However, the change is probably in the right direction.
Krepl M., Zgarbová M., Stadlbauer P., Otyepka M., Banáš P., Koča J., Cheatham TE I.I.I., Jurečka P, & Šponer J. (2012). Reference simulations of noncanonical nucleic acids with different χ variants of the AMBER force field: quadruplex DNA, quadruplex RNA and Z-DNA. Journal of chemical theory and computation, 8(7), 2506-2520.
Publication 2012
11-dehydrocorticosterone Amber Antibodies, Anti-DNA Cardiac Glycosides Deoxyribonucleosides Helix (Snails) Ribonucleosides Vertebral Column Vision
3
Quantum Mechanical Study of RNA 2'-Hydroxyl Rotation
Cited 14 times
QM calculations were performed using the program Gaussian0340 to obtain an estimate of the potential
energy associated with rotation of the 2′-hydroxyl moiety. The RNA
backbone dihedrals (α: P-O5′, β:
O5′-C5′, γ: C5′-C4′, δ:
C4′-C3′, ε: C3′-O3′, and ζ:
O3′-P) or the RNA glycosidic linkage dihedral (χ:
C1′-N1/N9) were fixed while dihedral potential energy scans were
performed for the 2′-hydroxyl as previously described 41 (link). Scans were performed at the MP2/6-31+G(d)
level of theory followed by single point calculations at the RIMP2/cc-pVTZ level
performed using the Q-Chem program 42 (link).
This level of theory has previously been shown to be sufficiently accurate for a
number of systems.25 ,43 (link) For this study, the 2′-hydroxyl dihedral
angle is defined with the respect to
C1′-C2′-O2′-H2′ (note that the atom names are
representative of those in the CHARMM27 all-atom additive nucleic acid force
field). The dihedral was scanned at 15° intervals from 0° to
360° for each of the compounds. Analogous potential-energy scans were
performed using the original CHARMM27 all-atom additive force field and several
trial revisions of the force field developed in the present study. Empirical
scans were performed using the same constraints as in the QM scans, implemented
as a harmonic potential with force constant 10,000 kcal/mol/rad2 (link) on the respective backbone and glycosidic linkage
dihedrals, with the remaining degrees of freedom optimized using the
Newton-Raphson algorithm to a final root-means-square (RMS) gradient of
10−6 kcal/mol/Å. All nonbonded interactions were
included in the calculations.
Denning E.J., Priyakumar U.D., Nilsson L, & MacKerell AD J.r. (2011). Impact of 2′-hydroxyl sampling on the conformational properties of RNA: Update of the CHARMM all-atom additive force field for RNA. Journal of computational chemistry, 32(9), 1929-1943.
Publication 2011
Cardiac Glycosides Hydroxyl Radical Nucleic Acids Plant Roots Radionuclide Imaging Vertebral Column
4
Measurement of MBG and Ouabain Levels
Cited 13 times
For measurement of MBG and endogenous ouabain, samples of plasma and urine were extracted on SepPak C-18 cartridges (Waters, Milford, Massachusetts, USA) as described previously in detail [11 (link)]. The MBG DELFIA fluoroimmunoassays based on anti-MBG 3E9 and 4G4 mAbs were performed as previously described for rabbit anti-MBG polyclonal antibodies [11 (link)]. The assay is based on competition between immobilized antigen (MBG-glycoside-thyroglobulin) and MBG, other cross-reactants, or endogenous CTS within the sample for a limited number of binding sites on an anti-MBG mAbs. Secondary (goat antimouse) antibody labeled with non-radioactive europium was obtained from Perkin-Elmer (Waltham, Massachusetts, USA).
The endogenous ouabain assay was based on a similar principle utilizing an ouabain–ovalbumin conjugate and ouabain antiserum (anti-OU-M-2005; 1 : 20 000) obtained from rabbits immunized with a ouabain-BSA conjugate [20 (link)]. The cross-reactivity of this ouabain antibody is (%) ouabain, 100; ouabagenin, 52, digoxin, 1.8; digitoxin, 0.47; progesterone, 0.002; prednisone, 0.001; proscillaridin, 0.03; bufalin, 0.10; aldosterone, 0.04; telocinobufagin, 0.02; resibufagin, 0.15; marinobufotoxin, 0.06; cinobufagin, 0.02; and MBG, 0.036.
Fedorova O.V., Simbirtsev A.S., Kolodkin N.I., Kotov A.Y., Agalakova N.I., Kashkin V.A., Tapilskaya N.I., Bzhelyansky A., Reznik V.A., Frolova E.V., Nikitina E.R., Budny G.V., Longo D.L., Lakatta E.G, & Bagrov A.Y. (2008). Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. Journal of hypertension, 26(12), 2414-2425.
Publication 2008
Aldosterone Anti-Antibodies Antigens Binding Sites Biological Assay bufalin Cardiac Glycosides cinobufagin Cross Reactions Digitoxin Digoxin Europium Fluoroimmunoassay Goat Immune Sera Immunoglobulins marinobufotoxin Monoclonal Antibodies Oryctolagus cuniculus ouabagenin Ouabain Ovalbumin Plasma Prednisone Progesterone Proscillaridin Rabbits telocinobufagin Thyroglobulin Urine
5
Cognitive Decline Risk Factors Protocol
Cited 12 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Apolipoproteins E Blood Pressure Cardiac Glycosides Cerebrovascular Accident Childbirth Cognition Dementia Depressive Symptoms Diabetes Mellitus Diagnosis Diastole Diet Digitoxin DNA Library Food High Blood Pressures Index, Body Mass Interviewers Lanoxin Myocardial Infarction Neurologic Examination Pharmaceutical Preparations Systole

Most recents protocols related to «Cardiac Glycosides»

1
Synthetic Procedure for Triterpenoid Compound
Not available on PMC !

Example 13

White solid. 1H NMR (CD3OD): 5.13 (d, J=1.4 Hz, 1H, H-1′), 5.13 (t, J=7.1 Hz, 1H, H-24), 3.79 (m, 1H, H-2′), 3.79 (m, 1H, H-5′), 3.60 (td, J=10.1, 5.5 Hz, 1H, H-12), 3.56 (dd, J=9.6, 3.2 Hz, 1H, H-3′), 3.38 (t-like, J=9.6, 9.2 Hz, 1H, H-4), 3.13 (dd, J=11.5, 4.6 Hz, 1H, H-3), 1.69 (s, 3H), 1.62 (s, 3H), 1.36 (s, 3H), 1.24 (d, J=6.0 Hz, 3H, H-5′), 1.00 (s, 3H), 0.96 (s, 3H), 0.93 (s, 3H), 0.91 (s, 3H), 0.77 (s, 3H); MS: 629[M+Na]+, 607[M+H]+, 589.5[M-OH]+, 443.4, 425.4, 407.4.

US11866458B2. Panaxadiol glycoside derivative and preparation method and application thereof (2024-01-09). SUZHOU JI ER BIOLOGICAL MEDICINE CO., LTD. [CN]. Inventors: Quanhai Liu [CN], Jun Zhang [CN].
Full text: Click here
Patent 2024
1H NMR Cardiac Glycosides panaxadiol
2
Structural Characterization of Bioactive Compound
Not available on PMC !

Example 12

White solid. 1H NMR (CD3OD): 5.09 (t, J=7.1 Hz, 1H, H-24), 4.52 (d, J=7.7 Hz, 1H, H-1′), 3.78 (dd, J=11.5, 5.5 Hz, 1H, H-5′-2), 3.68 (td, J=10.4, 4.9 Hz, 1H, H-12), 3.45 (ddd, J=10.4, 8.8, 5.5 Hz, 1H, H-4′), 3.29 (t, J=8.8 Hz, 1H, H-3′), 3.14 (dd, J=11.5, 10.4 Hz, 1H, H-5′-1), 3.13 (dd, J=11.0, 4.4 Hz, 1H, H-3), 3.07 (dd, J=8.8, 7.7 Hz, 1H, H-12), 1.67 (s, 3H), 1.61 (s, 3H), 1.32 (s, 3H), 1.00 (s, 3H), 0.96 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 0.70 (s, 3H); 13C NMR (CDCl3): 132.3 (C-25), 128.2 (C-24), 98.9 (C-1′), 84.8 (C-20), 79.6 (C-3), 78.4 (C-3′), 75.3 (C-2′), 71.8 (C-12), 71.1 (C-4′), 66.8 (C-5′), 57.3, 53.1, 52.4, 51.0, 40.9, 40.2, 40.0, 38.1, 36.7, 35.9, 31.5, 30.8, 28.6, 28.0, 27.2, 25.9, 23.9, 22.4, 19.4, 18.3, 17.8, 17.3, 16.7, 16.3, 16.1.

US11866458B2. Panaxadiol glycoside derivative and preparation method and application thereof (2024-01-09). SUZHOU JI ER BIOLOGICAL MEDICINE CO., LTD. [CN]. Inventors: Quanhai Liu [CN], Jun Zhang [CN].
Full text: Click here
Patent 2024
1H NMR Carbon-13 Magnetic Resonance Spectroscopy Cardiac Glycosides panaxadiol
3
Structural Elucidation of a Bioactive Compound
Not available on PMC !

Example 14

White solid. 1H NMR (CD3OD): 5.10 (d, J=7.3 Hz, 1H, H-24), 4.50 (d, J=7.3 Hz, 1H, H-1), 3.84 (dd, J=12.4, 1.4 Hz, 1H, H-5′-1), 3.79 (brs, 1H, H-4′), 3.71 (td, J=10.6, 5.5 Hz, 1H, H-12), 3.53 (dd, J=12.4, 1.4 Hz, 1H, H-5′-2), 3.51 (dd, J=6.4, 3.2 Hz, 1H, H-3′), 3.45 (dd, J=9.1, 7.3 Hz, 1H, H-2′), 3.14 (dd, J=11.5, 4.6 Hz, 1H, H-3), 1.67 (s, 3H), 1.62 (s, 3H), 1.34 (s, 3H), 1.01 (s, 3H), 0.96 (s, 3H), 0.92 (s, 3H), 0.91 (s, 3H), 0.78 (s, 3H).

US11866458B2. Panaxadiol glycoside derivative and preparation method and application thereof (2024-01-09). SUZHOU JI ER BIOLOGICAL MEDICINE CO., LTD. [CN]. Inventors: Quanhai Liu [CN], Jun Zhang [CN].
Full text: Click here
Patent 2024
1H NMR Cardiac Glycosides panaxadiol
4
Molecular Docking Analysis of Aucubin's Therapeutic Potential

Eucommia ulmoides Oliver (EUO) has a long history of medicinal use in China. As a medicinal plant used for tonifying kidney, strengthening bones, relieving pain, and enhancing immunity, EUO is also widely used in the treatment of RA, depression, and osteoporosis. The aqueous extract of EUO has been demonstrated to have a cartilage-protecting effect in a rat model of osteoarthritis, potentially by inhibiting chondrocyte apoptosis and improving cartilage metabolism (35 (link)). Aucubin (AU), an iridoid glycoside that is an active constituent of EUO, has been extensively studied for the management of neurological diseases (36 (link)). However, a comprehensive review of its effects and mechanisms is currently unavailable. Therefore, in this study, we investigated the therapeutic potential of AU. The utilization of molecular docking, a technique commonly employed in virtual screening studies, was carried out to identify potential therapeutic targets for AU (37 (link)).
Primarily, the cheminformatics of Aucubin (AU) was obtained from the PubChem database (38 (link)) (https://pubchem.ncbi.nlm.nih.gov/), which included chemical name, molecular formula, CAS, PubChem CID, canonical SMILES, and SDF files. The ACD/Labs software (https://www.acdlabs.com/), SwissADME online system (39 (link)) (http://www.swissadme.ch/) and ADMETlab 2.0 (https://admetmesh.scbdd.com/) (40 (link))were used to evaluate the pharmacokinetics and safety profile of AU, including absorption, distribution, metabolism, excretion, and toxicity. PyMOL software (version 1.7.0; https://pymol.org/) converted AU’s 3D structure, which was downloaded from the PubChem database (41 (link)) (http://www.rcsb.org/), from an SDF file to a PDB file while minimizing the energy of small molecules and then saved it as a PDBQT format file. The 3D structures of potential targets were downloaded from the PDB database (http://www.rcsb.org/). PyMOL software removed water molecules and hetero-ions from the PDB file of the target protein. The protein ligands then underwent hydrogenation and the charge was added in AutoDockTools (42 (link)) (version 1.5.6) software. Finally, the data were saved as a PDBQT file. The docking box parameters were determined based on the binding region of the protein receptor and original ligand, and the box size was set to 30Å × 30 Å × 30 Å. AutoDock Vina (version 1.1.2; http://vina.scripps.edu/) software performs refined the semi-flexible molecular docking and calculated the affinity (kcal/mol) of all potential key targets for AU. Generally, the lower the affinity value, the stronger the binding of the small molecule to the receptor. Discovery Studio Visualizer (https://www.3ds.com/) was used to visualize the 2D schemes of the AU-target protein interaction.
Zhou T.T., Sun J.J., Tang L.D., Yuan Y., Wang J.Y, & Zhang L. (2023). Potential diagnostic markers and therapeutic targets for rheumatoid arthritis with comorbid depression based on bioinformatics analysis. Frontiers in Immunology, 14, 1007624.
Full text: Click here
Publication 2023
Apoptosis aucubin Bones Cardiac Glycosides Cartilage Chondrocyte Degenerative Arthritides Disease Management Drug Kinetics Eucommia ulmoides Hydrogenation Ions Iridoids Kidney Ligands Metabolism Osteoporosis Pain Plants, Medicinal Protein Domain Proteins Protein Targeting, Cellular Response, Immune Safety Therapeutics
5
Conformational Dynamics of Human IgG1 Antibody
RMSD, RMSF and Rg were computed on C-alpha atoms by MDTraj38 (link). The analysis of cMD was performed on the concatenated replicas of each system excluding the first 300 ns that were considered as equilibration steps. The movement of Fab domains was described by means of ϕ (longitude) and θ (latitude) angles defined in a reference frame jointed to Fc and centered in the hinge with axes defined as follows: z axis collinear to Fc and directed toward Fabs, x axis parallel to a vector joining mid-Fc (CH2 regions) and y axis defined by right hand rule. For a more detailed description see the work by Saporiti et al.20 (link) An arbitrary threshold of 85° was chosen for θ angle to discriminate between Y- and T-shaped conformations. Specifically, we considered that the only one fully crystalized human IgG1 (PDB ID: 1HZH)31 (link), that is classified as a T-shaped conformation39 (link), presents θ > 90° for both Fab domains, and we took into account also the conformational variability expected from MD simulations. The distance between the CH2 domains was measured between the glycosylated Asn using MDTraj38 (link). Then, box plots were produced to evaluate the statistical significance of the observed values in the total 21,000 frames. For the aMD, a reweighing procedure was applied according to methods described by Miao et al.40 (link) using Maclaurin expansion to the 10th order to approximate the free energy surface of the system as a function of θ angles. The RMSD matrices for the cluster analysis (of both cMD and aMD) were generated with CPPTRAJ41 (link), while the clusters were obtained using a customized script based on the GROMOS algorithm42 (link). In the case of antibodies C-alpha atoms were considered for the analysis, while for glycans the oxygens involved in glycosidic bonds. RMSD-threshold of 7.5 Å and 6.5 Å were used for the antibodies in cMD and aMD, respectively, and the maximum number of clusters was set to 15 and 10, respectively. For glycans clustering the RMSD-threshold was set to 1 Å and the maximum number of clusters to 10. The essential dynamics (ED) was computed on the overall trajectories by the covariance analysis tool of GROMACS 2020.120 (link),43 (link). Then, the resulting trajectories, projected along the first and the second eigenvectors, were filtered by the frames included in the energy minimum that was identified from the FES (computed as function of θ angles) and were used to calculate the Δϕ distribution. The minimum distance between glycan chains was computed by CPPTRAJ41 (link) and the “nativecontacts” tool with the “mindist” option, while the distance between the center of mass of each chain and itself was computed with the “distance” tool. For the latter, the trajectories were pre-aligned on the Fc. The contacts between LCs and the hinge region were computed by CPPTRAJ41 (link) with the “nativecontacts” tool, considering heavy atoms and a threshold distance of 4 Å. The hydrogen bonds (H-bonds) analysis was computed by a customized python script based on the MDTraj H-bonds identification tool20 (link).
Saporiti S., Laurenzi T., Guerrini U., Coppa C., Palinsky W., Benigno G., Palazzolo L., Ben Mariem O., Montavoci L., Rossi M., Centola F, & Eberini I. (2023). Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility. Communications Biology, 6, 237.
Full text: Click here
Publication 2023
Antibodies Cardiac Glycosides Cloning Vectors Epistropheus Homo sapiens Hydrogen Bonds IgG1 Movement Oxygen Polysaccharides Python Strains

Top products related to «Cardiac Glycosides»

1
Digoxin by Merck Group
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, France
Digoxin is a laboratory product used for the detection and measurement of digoxin levels in biological samples. It is a cardiac glycoside extracted from the foxglove plant (Digitalis purpurea) and is commonly used in the management of certain heart conditions. The product provides a standardized and reliable method for quantifying digoxin concentrations, which is essential for therapeutic drug monitoring and patient care.
2
Agilent 5977b by Agilent Technologies
Sourced in United States, Belgium
The Agilent 5977B is a gas chromatograph-mass spectrometer (GC-MS) system designed for high-performance analytical applications. It provides accurate identification and quantification of chemical compounds in complex samples. The system combines a high-resolution gas chromatograph with a single quadrupole mass spectrometer to enable precise separation, detection, and analysis of volatile and semi-volatile compounds.
3
Uv 1800 by Shimadzu
Sourced in Japan, United States, Germany, Switzerland, China, United Kingdom, Italy, Belgium, France, India
The UV-1800 is a UV-Visible spectrophotometer manufactured by Shimadzu. It is designed to measure the absorbance or transmittance of light in the ultraviolet and visible wavelength regions. The UV-1800 can be used to analyze the concentration and purity of various samples, such as organic compounds, proteins, and DNA.
4
Ouabain by Merck Group
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Macao, India, France, Denmark, Poland
Ouabain is a cardiac glycoside that is used as a reference standard and research tool in the study of cardiac function and ion transport mechanisms. It acts by inhibiting the Na+/K+ ATPase pump, which is essential for maintaining the electrochemical gradient across the cell membrane. Ouabain is commonly used in various in vitro and in vivo experiments, particularly in the fields of physiology, pharmacology, and biochemistry.
5
Rxi 5 sil ms column by Shimadzu
Sourced in Japan
The RXI-5 SIL MS column is a capillary column designed for gas chromatography-mass spectrometry (GC-MS) analysis. It features a 5% phenyl-type stationary phase that provides good separation of a wide range of compounds. The column dimensions are 30 m length, 0.25 mm internal diameter, and 0.25 μm film thickness.
6
Hp 5ms capillary column by Agilent Technologies
Sourced in United States, Germany, United Kingdom, Italy, Canada
The HP-5MS capillary column is a gas chromatography column designed for a wide range of applications. It features a 5% phenyl-methylpolysiloxane stationary phase and is suitable for the separation and analysis of a variety of organic compounds.
7
Fluorescent brightener m2r by Merck Group
Sourced in United States
Fluorescent Brightener M2R is a laboratory product manufactured by Merck Group. It is a chemical compound used to enhance the fluorescence of various materials. The core function of this product is to increase the brightness and clarity of fluorescent signals in laboratory analyses and experiments.
8
Gcms qp2010 by Shimadzu
Sourced in Japan, United States, Germany, United Kingdom, Italy, France
The GCMS-QP2010 is a gas chromatograph-mass spectrometer system manufactured by Shimadzu. It is designed for the analysis and identification of chemical compounds in complex samples. The system combines a high-performance gas chromatograph with a sensitive quadrupole mass spectrometer to provide accurate and reliable analytical results.
9
β 1 3 d glucanase by Merck Group
Sourced in United States
β-1,3-d-glucanase is an enzyme that catalyzes the hydrolysis of β-1,3-glucan, a major structural component of the cell walls of certain fungi and plants. It is commonly used in laboratory settings for various research and analytical applications.
10
Xterra c18 column by Agilent Technologies
The XTerra C18 column is a high-performance liquid chromatography (HPLC) column designed for the separation and analysis of a wide range of analytes. It features a chemically bonded C18 stationary phase, which provides excellent retention and selectivity for a variety of compounds. The column is constructed with high-purity silica particles, ensuring efficient and reproducible chromatographic performance.

More about "Cardiac Glycosides"

Cardiac glycosides, also known as cardenolides, are a class of naturally occurring compounds derived from plants that have a direct impact on the heart.
These compounds, including the well-known digoxin and ouabain, interact with the sodium-potassium ATPase pump, altering the electrical activity and contractility of cardiac muscle cells.
Cardiac glycosides are commonly used in the treatment of certain heart conditions, such as atrial fibrillation and heart failure, where they can help improve heart function and reduce symptoms.
Researchers studying the therapeutic potential and mechanisms of cardiac glycosides can utilize PubCompare.ai's AI-driven platform to easily identify optimized research protocols from the literature, preprints, and patents, ensuring their work is accurate and reproducible.
This platform leverages advanced AI and machine learning algorithms to compare and analyze vast amounts of scientific data, making it easier to discover the most effective methods for working with cardiac glycosides.
In addition to digoxin, other relevant compounds and technologies that may be of interest to cardiac glycoside researchers include ouabain, a potent cardiac glycoside that can be used to study the effects of these compounds on the heart, as well as specialized analytical instruments like the Agilent 5977B GC-MS system and the UV-1800 spectrophotometer, which can be used to detect and quantify cardiac glycosides in various samples.
The RXI-5 SIL MS column and HP-5MS capillary column may also be useful for separating and analyzing these compounds using chromatographic techniques.
Furthermore, researchers may find the use of fluorescent brighteners, such as Fluorescent Brightener M2R, helpful in studying the cellular and molecular mechanisms of cardiac glycosides, as these compounds can be used to label and visualize specific cellular structures or processes.
The GCMS-QP2010 gas chromatography-mass spectrometry system and the XTerra C18 column are additional tools that may aid in the identification and quantification of cardiac glycosides and their metabolites.
Overall, the combination of PubCompare.ai's AI-driven platform and the various analytical tools and compounds mentioned can greatly enhance the efficiency and accuracy of cardiac glycoside research, paving the way for future advancements in the understanding and clinical application of these important natural compounds.